313 related articles for article (PubMed ID: 29327284)
1. Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
Di Gregorio M; Gaetani L; Eusebi P; Floridi P; Picchioni A; Rosi G; Mancini A; Floridi C; Baschieri F; Gentili L; Sarchielli P; Calabresi P; Di Filippo M
J Neurol; 2018 Mar; 265(3):522-529. PubMed ID: 29327284
[TBL] [Abstract][Full Text] [Related]
2. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years.
Bagnato F; Jeffries N; Richert ND; Stone RD; Ohayon JM; McFarland HF; Frank JA
Brain; 2003 Aug; 126(Pt 8):1782-9. PubMed ID: 12821527
[TBL] [Abstract][Full Text] [Related]
3. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Zivadinov R; Rudick RA; De Masi R; Nasuelli D; Ukmar M; Pozzi-Mucelli RS; Grop A; Cazzato G; Zorzon M
Neurology; 2001 Oct; 57(7):1239-47. PubMed ID: 11591843
[TBL] [Abstract][Full Text] [Related]
4. Diffusion basis spectrum imaging and diffusion tensor imaging predict persistent black hole formation in multiple sclerosis.
Wooliscroft L; Salter A; Adusumilli G; Levasseur VA; Sun P; Lancia S; Perantie DC; Trinkaus K; Naismith RT; Song SK; Cross AH
Mult Scler Relat Disord; 2024 Apr; 84():105494. PubMed ID: 38359694
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Zivadinov R; Zorzon M; De Masi R; Nasuelli D; Cazzato G
J Neurol Sci; 2008 Apr; 267(1-2):28-35. PubMed ID: 17945260
[TBL] [Abstract][Full Text] [Related]
6. Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
Rao AB; Richert N; Howard T; Lewis BK; Bash CN; McFarland HF; Frank JA
Neurology; 2002 Sep; 59(5):688-94. PubMed ID: 12221158
[TBL] [Abstract][Full Text] [Related]
7. Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis.
van den Elskamp IJ; Lembcke J; Dattola V; Beckmann K; Pohl C; Hong W; Sandbrink R; Wagner K; Knol DL; Uitdehaag B; Barkhof F
Mult Scler; 2008 Jul; 14(6):764-9. PubMed ID: 18611989
[TBL] [Abstract][Full Text] [Related]
8. Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis.
Calvi A; Tur C; Chard D; Stutters J; Ciccarelli O; Cortese R; Battaglini M; Pietroboni A; De Riz M; Galimberti D; Scarpini E; De Stefano N; Prados F; Barkhof F
Neuroimage Clin; 2022; 35():103048. PubMed ID: 35598462
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
Visser LH; Beekman R; Tijssen CC; Uitdehaag BM; Lee ML; Movig KL; Lenderink AW
Mult Scler; 2004 Feb; 10(1):89-91. PubMed ID: 14760960
[TBL] [Abstract][Full Text] [Related]
10. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
Nos C; Sastre-Garriga J; Borràs C; Río J; Tintoré M; Montalban X
Mult Scler; 2004 Aug; 10(4):413-6. PubMed ID: 15327039
[TBL] [Abstract][Full Text] [Related]
12. Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.
Fox RJ; Fisher E; Tkach J; Lee JC; Cohen JA; Rudick RA
Mult Scler; 2005 Apr; 11(2):140-5. PubMed ID: 15794385
[TBL] [Abstract][Full Text] [Related]
13. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
De Stefano N; Filippi M; Hawkins C;
J Neurol Sci; 2008 Mar; 266(1-2):44-50. PubMed ID: 17897678
[TBL] [Abstract][Full Text] [Related]
14. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Perumal JS; Caon C; Hreha S; Zabad R; Tselis A; Lisak R; Khan O
Eur J Neurol; 2008 Jul; 15(7):677-80. PubMed ID: 18459972
[TBL] [Abstract][Full Text] [Related]
15. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP
BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.
Gupta S; Solomon JM; Tasciyan TA; Cao MM; Stone RD; Ostuni JL; Ohayon JM; Muraro PA; Frank JA; Richert ND; McFarland HF; Bagnato F
Mult Scler; 2005 Dec; 11(6):658-68. PubMed ID: 16320725
[TBL] [Abstract][Full Text] [Related]
17. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
[TBL] [Abstract][Full Text] [Related]
18. Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA; Imrey PB; Calabresi PA; Edwards KR; Eickenhorst T; Felton WL; Fisher E; Fox RJ; Goodman AD; Hara-Cleaver C; Hutton GJ; Mandell BF; Scott TF; Zhang H; Apperson-Hansen C; Beck GJ; Houghtaling PL; Karafa MT; Stadtler M;
Neurology; 2009 Feb; 72(6):535-41. PubMed ID: 19204263
[TBL] [Abstract][Full Text] [Related]
19. Effect of fingolimod on diffuse brain tissue damage in relapsing-remitting multiple sclerosis patients.
De Stefano N; Tomic D; Radue EW; Sprenger T; Meier DP; Häring D; Sormani MP
Mult Scler Relat Disord; 2016 May; 7():98-101. PubMed ID: 27237768
[TBL] [Abstract][Full Text] [Related]
20. Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
De Andres C; García MI; Goicoechea H; Martínez-Ginés ML; García-Domínguez JM; Martín ML; Romero-Delgado F; Benguría A; Sanjurjo M; López-Fernández LA
Pharmacogenomics J; 2018 Jan; 18(1):98-105. PubMed ID: 27670768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
